
Keywords: CTLA-4; cytotoxic T-lymphocyte-associated protein 4; ICI; immune checkpoint inhibitor; irAE; immune-related adverse event; mRSS; modified Rodnan skin score; PD-1; programmed cell death 1; PD-L1; programmed cell death ligand 1; RNAP3; RNA polymerase III;